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Background: The aim of the project was to develop a novel method for diabetic retinopathy screening based on
the examination of tear fluid biomarker changes. In order to evaluate the usability of protein biomarkers for pre-
screening purposes several different approaches were used, including machine learning algorithms.
Methods: All persons involved in the study had diabetes. Diabetic retinopathy (DR) was diagnosed by capturing 7-
field fundus images, evaluated by two independent ophthalmologists. 165 eyes were examined (from 119 patients),
55 were diagnosed healthy and 110 images showed signs of DR. Tear samples were taken from all eyes and state-
of-the-art nano-HPLC coupled ESI-MS/MS mass spectrometry protein identification was performed on all samples.
Applicability of protein biomarkers was evaluated by six different optimally parameterized machine learning
algorithms: Support Vector Machine, Recursive Partitioning, Random Forest, Naive Bayes, Logistic Regression,
K-Nearest Neighbor.
Results: Out of the six investigated machine learning algorithms the result of Recursive Partitioning proved to be
the most accurate. The performance of the system realizing the above algorithm reached 74% sensitivity and 48%
specificity.
Conclusions: Protein biomarkers selected and classified with machine learning algorithms alone are at present not
recommended for screening purposes because of low specificity and sensitivity values. This tool can be potentially
used to improve the results of image processing methods as a complementary tool in automatic or semiautomatic
systems.
Keywords: Diabetic retinopathy screening, Tear fluid biomarkers, Quantitative mass spectrometry, Pattern
recognitionBackground
Diabetic retinopathy screening
Diabetic retinopathy (DR) is the most common complica-
tion of diabetes mellitus and is currently the leading cause
of blindness in the economically active population in de-
veloped countries [1]. The initially latent disease could
lead to vision loss without any symptoms initially. Timely
diagnosis and therapy however can significantly decelerate
its progress, necessitating regular DR screening or appro-
priate follow-up in all patients with diabetes. Screening* Correspondence: zsolt.torok@astridbio.com
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reproduction in any medium, provided the orcan be carried out by direct and indirect ophthalmology
or increasingly by using photographic methods [2].
The effectiveness of different screening modalities has
been widely investigated. UK studies show sensitivity
levels for the detection of sight-threatening diabetic ret-
inopathy of 41-67% for general practitioners, 48-82% for
optometrists, 65% for ophthalmologists, and 27-67% for
diabetologists and hospital physicians using direct oph-
thalmoscopy [3,4]. Sensitivity for the detection of refer-
able retinopathy by optometrists have been found to be
77-100%, with specificity of 94-100% [5].
Photographic methods currently use digital images
with subsequent grading by trained individuals. Sensitiv-
ity for the detection of sight-threatening diabetic retin-
opathy have been found 87-100% for a variety of trainedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with specificities of 83-96% [6]. The British Diabetic As-
sociation (Diabetes UK) has established standard values
for any diabetic retinopathy screening programme of at
least 80% sensitivity and 95% specificity [7,8].
Regular DR screening is centralized in several developed
countries due to cost-efficiency and quality control issues
[9]. Digital fundus images are captured at the place of pa-
tient care and forwarded to a grading center for evaluation
by specially trained human graders or ophthalmologists
[10]. The system operates with high accuracy but due to
its labor intensive nature, it might be poorly scalable in
economically challenged countries [11].
In order to improve scalability and cost-effectiveness,
many research groups are working on developing auto-
mated image analysis technologies [12]. Introducing
these technologies in DR screening could substitute first
phase examinations performed by human graders. Fol-
lowing automated pre-screening, human graders would
only have to examine images that are either questionable
or true positive, and potentially carry out quality control
on a subset of those deemed normal by the software
[13]. Preliminary results are promising, sensitivity and
specificity indicators of automated systems are close to
that of human graders [14-16]. An international Retin-
opathy Online Challenge is available in order to compare
the results of image processing based algorithms for DR
identification via mycroaneurism detection. The system
developed by our team currently performs the best on
this challenge [17].
The aim of this paper is to describe a pilot study,
conducted as a first attempt to examine the use of tear
fluid proteomics for DR pre-screening. Our hypothesis
was that it is possible to categorize patients with un-
known clinical status into a DR or a non-DR group,
based on the protein pattern identified in the tear fluid
sample.
Tear fluid proteomics
Besides computer based image processing other methods
can also support DR screening. Tear fluid proteomics is
such a possible novel tool for population screening,
which is based on the pre-screening of a large number
of patients and uses human graders only in positive or
ambiguous cases. The protein composition of tear fluid
has been investigated by numerous research groups and
more than 500 proteins are already proven to be present
there [18,19]. Reports confirm protein profile changes in
tear fluid under irregular physiological and pathological
conditions (like wound healing or inflammatory diseases
etc.) [20]. Besides the proteins secreted by the lacrimal
glands, tear fluid might contain proteins from epithelial
cells covering the eye surface. Furthermore proteins nor-
mally residing in the blood can get into the tear fluidthrough increased permeability of the conjunctival ves-
sels [21].
Physiological and pathological conditions of the retina
also induce changes in the protein composition of the vit-
reous humour, especially when the blood-retinal barrier
(BRB) is damaged [22]. Breakdown of the inner endothe-
lial BRB, occurs in diabetic retinopathy, age-related macu-
lar degeneration, retinal vein occlusions, uveitis and other
chronic retinal diseases [23]. DR is a complex disease,
characterized by vascular alterations, inflammation, and
neuronal cell death that involve heat-shock and crystalline
proteins. The central mechanism of altered BRB function
is a change in the permeability characteristics of retinal
endothelial cells caused by elevated levels of growth fac-
tors, cytokines, advanced glycation end products, inflam-
mation, hyperglycemia and loss of pericytes. Subsequently,
paracellular but also transcellular transport across the ret-
inal vascular wall increases via opening of endothelial
intercellular junctions and qualitative and quantitative
changes in endothelial caveolar transcellular transport, re-
spectively. Functional changes in pericytes and astrocytes,
as well as structural changes in the composition of the
endothelial glycocalyx and the basal lamina around BRB
endothelium further facilitate BRB leakage. As Starling's
rules apply, active transcellular transport of plasma pro-
teins by the BRB endothelial cells causing increased inter-
stitial osmotic pressure is probably the main factor in the
formation of macular edema [23]. Recent studies using
whole proteome analysis demonstrate that general stress
response lead to the induction of heat-shock proteins. The
alpha-crystallin is expressed in the retina and over-
expressed during diabetes as an adaptive response of ret-
inal cells [24]. These changes are more specific to DR than
alteration of tear fluid proteome. However, the invasive
sampling method makes it difficult to introduce vitreous
humour proteomics in the daily clinical practice.
According to recent publications the protein compos-
ition of tear fluid reflects normal or abnormal condi-
tions, which justifies the use of tear fluid for screening
purposes. Electrophoresis and chromatography also sup-
port that protein patterns of healthy and diabetic people
are significantly different [25,26].
Qualitative and quantitative methods used for tear
fluid examinations include one and two dimensional
electrophoresis, enzyme-linked immunosorbent assay
and high throughput liquid chromatography [27-29]. Re-
cently, high sensitivity and high resolution procedures
were used for the assessment of the effects of trauma
and various diseases in tear fluid of microliter quantity.
In these cases, protein profiles were characterized by
mass spectrometers MALDI-TOF, SELDI-TOF and LC/
MS [30-33].
In a previous study we examined the changes of tear
protein concentrations in DR aiming to identify and
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tear fluid in DR patients. Tear fluid samples were exam-
ined by quantitative mass spectrometry, and 6 potential
biomarkers namely lipocalin 1, lactotransferrin, lacritin,
lysozyme C, lipophilin A and immunoglobulin lambda
chain were identified. The results of that study have
already been published elsewhere [34].
In this paper, we evaluate the usefulness of the previ-
ously identified DR marker proteins in tear fluid sample
for diagnostic purposes and introduce a method based
on whole protein pattern analysis, which can be inte-
grated into the screening of DR as a pre-screening
procedure.
Machine learning
Machine learning is an area of artificial intelligence. IT
systems using machine learning methods are capable to
learn from training datasets and predict possible out-
comes based on new observations. In our case the input
data are coming from proteomics experiments and the
predicted outcomes are diseased and non-diseased cases
(DR or Non-DR). In the learning phase both input data
and outcomes are used by the system. During the pre-
screening process the trained machine learning system
will classify cases into diseased or non-diseased groups.
In our pilot study, we intended to ensure the objectiv-
ity of the assessment by using the following 6 different
machine learning methods: Support Vector Machine
(SVM), Recursive Partitioning (rpart), Random Forest
(randomForest), Naive Bayes (naïveBayes), Logistic Re-
gression (logReg), K-Nearest Neighbor (k-NN). Possible
positive and negative cases for DR can be identified by
machine learning algorithms, allowing the pre-screened
population (possible positives) to undergo human
screening by using digital retinal imaging. The approach
presented in this paper is unique in nature, as no previ-
ous study was found in the scientific literature investi-
gating the applicability of tear fluid proteomics based
methods for DR screening.
Methods
Patient examination
119 patients with diabetes were enrolled in the study. In
case of 73 patients one of the eyes were examined due
to difficulties in tear fluid sampling (e.g. keratoconjuncti-
vitis sicca, operated eye, noncompliance) or because
the retinal image couldn’t be taken (e.g. cataract,
hemorrhage, angle-closure glaucoma) or assessed (tech-
nical difficulties). Diabetic retinopathy was diagnosed by
capturing 7-field fundus images of the patients, evalu-
ated by two independent ophthalmologists. Megaplus
Camera Model 1,6i/10 BIT Zeiss (Carl Zeiss Ophthalmic
System A6, Jena, Germany) was used for taking images.
Out of the 165 eyes examined, 55 were diagnosedhealthy and 110 showed signs of DR. One patient had
DR in one eye only.
Tear fluid samples were collected from the examined
eyes by a trained assistant under standardized conditions
[35]. Tear samples were collected with glass capillaries
immediately before the pupil dilatation for fundus exam-
ination under slit lamp illumination from the lower tear
meniscus (a horizontal thickening of the pre-corneal tear
film by the lower margin) at the lateral canthus. Care
was taken not to touch the conjunctiva. The duration of
the sampling process was recorded and the secretion
rate was calculated in microl/min, dividing the obtained
tear volume by the time of sample collection. Samples
used in this investigation had secretion rates of 5–15 μl/
min. Samples were centrifuged (1800 rpm) for 8–10 mi-
nutes immediately after sample collection, supernatants
were deep-frozen at −80°C and were thawed only once
for measurements. Tear samples were examined using
state-of-the-art nano-HPLC coupled ESI-MS/MS mass
spectrometry protein identification as described elsewhere
[29]. During the protein-based screening procedure pre-
proliferative and proliferative retinopathy patients were
both considered important, the term ’patient’ includes
both groups diagnosed by using retina images. Global
pattern of protein concentrations and its changes were
described by the examination of the concentrations of
34 different proteins.
Application of machine learning methods
By using machine learning algorithms we intended to
predict the possible fulfillment of certain future events–
using empirical data containing incomplete information.
In the present special case, input data (features) are pro-
tein levels measured in tear fluids from patients with
diabetes and clinical data regarding their DR status (di-
chotomous variable of none or some). As the method is
designed to be used in screening in the future, high sen-
sitivity values were considered as the primary criteria for
the construction of the classifier. This was aimed at min-
imizing the number of false negative cases, thus redu-
cing the chance for missing sight threatening disease.
The goal of this machine learning approach is to assess
the best classification performance achievable by fitting
different models to the dataset (model selection). In
order to reach the best possible results, we tested several
classifying algorithms (SVM, rpart, randomForest,
naiveBayes, logReg, k-NN).
A further objective was to design a marker score for
marker selection, targeting the best performance of the
tested models. In order to guarantee comparability at
the parameter adjustment of the different classifiers, we
applied the settings providing the best performance re-
garding the particular model. In order to monitor the
classifier’s performance on the dataset, the testing was
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[36]. During the k-fold cross validation the data set is di-
vided into k equal parts. The first k-1 set (training set) is
used for model construction and later on it is tested on
the k-fold set (test set). In the further k-1 iteration the
same procedure is followed, on the first k-2 and k-fold
set the model is learning and on the k-1 it is validated.
At the end of the cross validation, the estimate is deter-
mined as the mean of the features of the k-fold model.
In this study 5-fold cross validation was used. Standard
measures were applied to assess the performance of the
different models, e.g.: specificity, sensitivity, accuracy, F-
measure (harmonic mean of precision and sensitivity–as
a single measure for the performance of the model).Data analysis software tools
We collected experimental (proteomics) and clinical
data (DR/Non-DR) in an Excel file which was used as in-
put data for the analysis.
During the data analysis process the R statistical frame-
work and the following packages have been used: Support
Vector Machine: “e1071”; Recursive Partitioning: “rpart”;
Random Forest: “randomForest”; Naive Bayes: “naiveBayes”;
Logistic Regression: “glmnet” and for visualization purpose:
“ggplot2” [37]. We have developed our own solution for the
K-Nearest Neighbor model.Table 1 Performance measures of the six different classifiers
Model Dataset SENS SPC ACC
naiveBayes orig 0.6991 0.4186 0.6218
marker 0.8000 0.3874 0.5064
pca 0.6731 0.3365 0.4487
kNN orig 0.6711 0.5000 0.6667
marker 0.6688 0.5000 0.6667
pca 0.6643 0.3077 0.6346
logReg orig 0.6923 0.3846 0.5897
marker 0.6615 0.3077 0.6026
pca 0.6623 0.0000 0.6538
randomForest orig 0.6929 0.4483 0.6474
marker 0.6923 0.4103 0.6218
pca 0.6748 0.3636 0.6090
rpart orig 0.7083 0.4722 0.6538
marker 0.7404 0.4808 0.6538
pca 0.6935 0.4375 0.6410
SVM orig 0.6645 0.0000 0.6603
marker 0.6623 0.0000 0.6538
pca 0.6623 0.0000 0.6538
Performance measures of the six different classifiers on the different input data: ori
data. The meaning of the columns: SENS-sensitivity, SPC-specificity, ACC-accuracy, P
measure, LRP- likelihood ratio positive, LRN-likelihood ratio negative.We ran cross validation using the three different ap-
proaches below in order to find the best combination of
input data and the different models.
First, we used data from all 34 identified proteins for
model development.
However, we also wanted to analyze the changes in the
performance of the classifiers if we only use a subset of
the data. Thus, second, only 6 marker proteins (out of
the 34)–previously extracted by classical statistical
methods–were used for decision making, applying the
six machine learning algorithms. Third, we wanted to
further evaluate the performance of the models by redu-
cing the number of input variables therefore we applied
principal component analysis (PCA). In this case, we
performed dimension reduction to compress the infor-
mation included in the original dataset with principal
component analysis and used it for the visualization of
the complex dataset in a 2D plane. With this method
the number of input features could be decreased while
as much of the variation in data as possible could be
retained. Thus, we had fewer input features which are
the linear combinations of the original variables and
uncorrelated with each other.
Statement of ethics
We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of humanPREC NPV F1 LRP LRN
0.7596 0.3462 0.7281 1.2025 0.7188
0.3462 0.8269 0.4832 1.3059 0.5163
0.3365 0.6731 0.4487 1.0145 0.9714
0.9808 0.0385 0.7969 1.3421 0.6579
0.9904 0.0192 0.7984 1.3377 0.6623
0.9135 0.0769 0.7692 0.9596 1.0909
0.6923 0.3846 0.6923 1.1250 0.8000
0.8269 0.1538 0.7350 0.9556 1.1000
0.9808 0.0000 0.7907 0.6623 Inf
0.8462 0.2500 0.7619 1.2559 0.6850
0.7788 0.3077 0.7330 1.1739 0.7500
0.7981 0.2308 0.7313 1.0604 0.8943
0.8173 0.3269 0.7589 1.3421 0.6176
0.7404 0.4808 0.7404 1.4259 0.5400
0.8269 0.2692 0.7544 1.2330 0.7005
0.9904 0.0000 0.7954 0.6645 Inf
0.9808 0.0000 0.7907 0.6623 Inf
0.9808 0.0000 0.7907 0.6623 Inf
g-full data set; marker- candidate marker proteins only; pca–PCA transformed
REC-precision (positive predictive value), NPV-negative predictive value, F1-F-
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and Institutional Ethics Committee, Medical and Health
Science Center, University of Debrecen).Results and discussion
Evaluation of the six classifiers on the data
Out of the six different machine learning algorithms,
rpart methodology was found to be the most efficient if
we used the dataset of the six marker proteins identified
by classical statistical methods. Standard measures
(Table 1) show that the model based on the Recursive
Partitioning classifier outperforms the other five models
(74% sensitivity, 48% specificity and 65% accuracy; rpart/
marker). Naive Bayes method shows higher sensitivity
but low specificity (38%), if we were using the marker
proteins only as input variables (80%; naiveBayes/
marker). Random Forest method performs slightly worse
than Recursive Partitioning.
Six proteins were identified as independent biomarkers
out of the 34 candidate protein, by using statistical hy-
pothesis testing.
There is additional information in the joint distribu-
tion of the whole dataset, thus we wanted to examine
the maximum possible performance of the model.Figure 1 Scatter plot. Scatter plot of the PCA transformed data set. X1 an
refers to non-DR, 1 refers to DR patients.Our reason for examining the performance of the re-
duced set was to develop a practical method for screen-
ing, without compromising the performance of the test.
We have found that neither the models built on just
the 6 marker proteins nor the models built on the PCA
preprocessed data performed better or worse than the
models built on the whole protein patterns. After Princi-
pal Component Analysis the first two components
retained 22% of the variation of the original data set.
Table 1 shows that in case of retaining the first two com-
ponents only, performance measures does not change
considerably. As a visual presentation of the data we
have generated a scatter plot of the first two compo-
nents. Figure 1 presents the lack of clear decision
boundary separating the two classes.
As part of our descriptive analysis we evaluated and vi-
sualized the correlation between the predictor variables
(protein levels) and also between predictor and outcome
variables (DR or non-DR) to have a better understanding
on the structure of the data set. According to the prob-
ability density function of the correlation values in most
of the cases there are low correlation between predictors
and predictors/outcomes (Figure 2). These figures sug-
gest that the predictors used separately will not be suffi-
cient for the classification.d X2 are the two components retained after the transformation. 0
Figure 2 Probability density function. Probability density function of the correlation values between predictors (on the left) and between
predictors and outcome variables (on the right).
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In order to evaluate the impact of the training set size
on the reliability of the results we compared the learning
curves for each of the cases. With this method we can
have an insight to the relation of the bias and variance
of the different models and also further improvementFigure 3 Learning curves. Learning curves of Support Vector Machine (SV
Naive Bayes (naiveBayes) classifiers for original data set.possibilities. For more accurate evaluation of the perform-
ance of our methods we have to examine if there are any
effects of increasing data volume on the performance of
the different machine learning methods (Figure 3).
We used learning curve to display the test and training
errors for different training set sizes.M), Recursive Partitioning (Rpart) Logistic Regression (Logreg) and
Torok et al. BMC Ophthalmology 2013, 13:40 Page 7 of 8
http://www.biomedcentral.com/1471-2415/13/40The distance of the curves shows a gap between the
error rates of training and test set in case of Support
Vector Machine (SVM) and Recursive Partitioning
(Rpart). This finding suggests that these classifiers have
high variance and getting more training data might help
with the performance. In case of Logistic Regression
(Logreg) and Naive Bayes (naiveBayes) we do not see a
gap, but both training and test errors are high, indicating
that the models are too simple, thus, we have underfit
the data.
Conclusions
We hypothesized at the beginning of the study, that the
system may be utilized for pre-screening purposes,
substantially-in long term-reducing the cost of regular
screening and the need for health professionals in the
process. A possible advantage of this method is that the
pre-screening of the risk population (i.e. diabetic pa-
tients) can be performed at the patient’s home. Patients
can take tear sample by their own, using sampling capil-
laries delivered by post, and then returning it to the la-
boratory. Only those with positive screening results
should visit a DR screening center.
Based on this pilot study, sensitivity and specificity
values of the system examined on a test database were
not found high enough to unequivocally support its use
as a pre-screening method prior to currently applied
screening procedures. However, the results of the system
may be further improved by the enlargement of the
learning database.
Another promising application of proteomics based
machine learning methods is the support of image pro-
cessing based automated methods by improving their
performance to be able to substitute traditional human
screening methods in the future. Given constantly drop-
ping price of high throughput technologies, methodolo-
gies based on such technologies will be available both
for routine point of care diagnostics and screenings [38].
On the other hand, costs of human workforce signifi-
cantly increase along with the decreasing accessibility of
qualified health care professionals. The net result of
these forces accelerates the future spread of such
technologies.
This study opens up the possibility of including fea-
tures other than protein analysis: e.g. anamnestic clinical
data, results of image processing procedures. Applying
more individual parameters as system inputs may con-
siderably improve the sensitivity indicators of a com-
bined system in contrast to the proteomics-alone or
image processing-alone systems. This statement is fur-
ther emphasized as the results of procedures based on
image processing are highly promising. The system built
on combined procedures may be applied in the future
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